Calliditas’ Phase IIb trial of PBC treatment meets primary endpoint
Setanaxib was also found to be well-tolerated in the trial.
26 July 2024
26 July 2024
Setanaxib was also found to be well-tolerated in the trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.